Novus Biologicals Announces New DEPDC6 Antibody made using SDIX's Genomic Antibody Technology™

Novus Biologicals announced today a new DEPDC6 Antibody (NBP1-49674) for the study of mTOR signaling and cancer treatment. This DEPDC6 antibody was made using SDIX's Genomic Antibody Technology™ (GAT™).

DEPDC6, also known as DEPTOR, is a negative regulator of the mTORC1 and 2 signaling pathways. The mTOR pathway is deregulated in certain cancers, so DEPDC6 is thought to be linked to tumor development. The DEPDC6 antibody may be used for Western blot and immunostaining of human and mouse samples, and will prove a useful tool for researchers studying mTOR signaling and cancer development.

GAT uses sophisticated bioinformatics and immunization strategies to produce high-quality antibodies that specifically bind to that region of the protein in its naturally folded form. The ability of any antibody to recognize a protein’s naturally folded state has the potential to expand an antibody’s utility to high-value applications like sandwich immunoassay, ChIP, and flow cytometry. Learn more about GAT by reading the GAT FAQ or by downloading the GAT White Paper.